Related Experiment Video
Updated: Jul 11, 2026
09:48
An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
Routine pelvic lymphadenectomy in apparently early stage endometrial cancer
L D Zuurendonk1, R A Smit, B W J Mol
1Department of Obstetrics and Gynaecology, St Elisabeth Hospital Tilburg, Tilburg, The Netherlands.
Summary
For early-stage endometrial cancer patients without risk factors, pelvic lymphadenectomy can be omitted, potentially reducing treatment burden. Further research is needed for optimal management in other patient groups.
Area of Science:
- Gynecologic Oncology
- Surgical Oncology
Background:
- Treatment decisions for endometrial cancer, particularly lymphadenectomy and adjuvant radiotherapy, remain subjects of debate.
- Accurate staging and risk stratification are crucial for optimizing patient outcomes.
Purpose of the Study:
- To evaluate the necessity of pelvic lymphadenectomy in early-stage endometrial cancer (FIGO Stage I).
- To determine if omitting lymphadenectomy in low-risk patients impacts survival or recurrence rates.
Main Methods:
- A retrospective study included 335 women with FIGO Stage I endometrial cancer (1998-2004).
- All patients underwent hysterectomy and bilateral salpingo-oophorectomy.
- Pelvic lymphadenectomy was performed in 237 patients; radiotherapy was guided by lymph node status or risk factors.
Main Results:
- Overall 5-year survival was 85.0% (absolute) and 93.7% (relative), with 8.5% loco-regional recurrence.
- In patients with lymphadenectomy and negative nodes, rates were 88.2%, 93.9%, and 5.6%, respectively.
- No lymph node metastases were found in 58 patients lacking risk factors (grade III, deep invasion, age ≥60).
Conclusions:
- Pelvic lymphadenectomy may be safely omitted in approximately 25% of FIGO Stage I endometrial cancer patients identified as low-risk.
- This approach can potentially reduce treatment morbidity without compromising oncologic outcomes in this specific subgroup.
- Optimal treatment strategies for higher-risk patients with endometrial cancer require continued investigation.
